Fibro Gide
Total Payments
$597,630
Transactions
29
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $79,649 | 9 | 3 |
| 2021 | $180,304 | 9 | 0 |
| 2020 | $337,677 | 11 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $597,630 | 29 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Evaluation of Geistlich Fibro-Gide in Comparison to CTG for the Treatment Around Implants | Geistlich Pharma, North America, Inc. | $294,205 | 2 |
| Evaluation of Geistlich FibroGide in comparison to CTG for the treatment around implants | Geistlich Pharma, North America, Inc. | $173,370 | 0 |
| Evaluation of Geistlich Fibro-Gide + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months | Geistlich Pharma, North America, Inc. | $71,476 | 0 |
| Evaluation of Geistlich Fibro-Gide and CAF in Comparison to CTG + CAF for the treatment of Recession Defects at 6 months | Geistlich Pharma, North America, Inc. | $31,547 | 0 |
| Evaluation of Geistlich Fibro-Gide+ CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months | Geistlich Pharma, North America, Inc. | $13,879 | 0 |
| Evaluation of Geistlich FibroGide + CAF in comparison to CTG + CAF for the treatment of recession Defects at 6 Months | Geistlich Pharma, North America, Inc. | $6,934 | 0 |
| Clinical and ultrasonographic outcomes of gingival recessions associated with non-carious cervical lesions treated with a novel volume-stable xenogeneic collagen matrix: a prospective case series | Geistlich Pharma, North America, Inc. | $6,218 | 1 |
Top Doctors Receiving Payments for Fibro Gide
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $536,611 | 26 |
| , DDS | Periodontics | Richmond, VA | $45,801 | 1 |
| , DDS, MS | Periodontics | Raleigh, NC | $9,000 | 1 |
| Lorenzo Tavelli | Periodontics | Cambridge, MA | $6,218 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Device
- Total Payments $597,630
- Total Doctors 3
- Transactions 29
About Fibro Gide
Fibro Gide is a device associated with $597,630 in payments to 3 healthcare providers, recorded across 29 transactions in the CMS Open Payments database. The primary manufacturer is Geistlich Pharma, North America, Inc..
Payment data is available from 2020 to 2022. In 2022, $79,649 was paid across 9 transactions to 3 doctors.
The most common payment nature for Fibro Gide is "Unspecified" ($597,630, 100.0% of total).
Fibro Gide is associated with 7 research studies, including "Evaluation of Geistlich Fibro-Gide in Comparison to CTG for the Treatment Around Implants" ($294,205).